Covetrus Inc
CVET
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
$22.33
6.4% upside
Current Fair Value
6.4% upsideUndervalued by 6.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $973.00 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.63 |
| Beta | 1.51 |
| Outstanding Shares | 140,000,000 |
Return
| Return on Equity | -0.86% |
|---|---|
| Return on Assets | -0.38% |
| Return on Invested Capital | 0.08% |
Valuation & Multiples
| P/E Ratio | -33.44 |
|---|---|
| PEG | 38.39 |
| Price to Sales | 0.64 |
| Price to Book Ratio | 2.1 |
| Enterprise Value to Revenue | 0.21 |
| Enterprise Value to EBIT | 486.5 |
| Enterprise Value to Net Income | -75 |
| Total Debt to Enterprise | 1.09 |
| Debt to Equity | 0.7 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Covetrus Inc
CEO: Benjamin Shaw Relevant Senate Committees
Finance
This committee controls taxation, trade, and entitlement spending, directly impacting corporate tax policy, Medicare/Medicaid drug reimbursement rates, and tariffs on pharmaceutical products, all crucial for Covetrus's profitability and operations.
Health, Education, Labor, and Pensions
This committee directly regulates the FDA, which is critical for drug approvals and safety relevant to pharmacies. It also influences labor laws impacting operational costs for retail businesses like Covetrus.